SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (9681)6/4/2008 5:44:30 PM
From: IRWIN JAMES FRANKEL  Respond to of 10345
 
Thanks

>> I wonder if tysabri (when it works) would obviate the need for the Acorda MS walking drug?

I'm sure it would if used early enough. Even the prior treatments slowed progression - T should do even better.

There is still plenty of people who will benefit by the ACOR drug. I know - I have been to the neuro with my wife and watched the people coming and going from an active MS practice.

ij


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News